What is B. Riley’s Forecast for Exagen Q3 Earnings?

Exagen Inc. (NASDAQ:XGN) – Equities researchers at B. Riley issued their Q3 2025 earnings per share estimates for Exagen in a research report issued to clients and investors on Wednesday, September 10th. B. Riley analyst A. Schock forecasts that the company will earn ($0.12) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. B. Riley also issued estimates for Exagen’s Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.01 EPS and FY2026 earnings at ($0.09) EPS.

Exagen (NASDAQ:XGN) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%.The company had revenue of $17.20 million during the quarter, compared to analyst estimates of $16.25 million. Exagen has set its FY 2025 guidance at EPS.

XGN has been the subject of several other reports. Canaccord Genuity Group raised their price objective on Exagen from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, July 30th. Craig Hallum began coverage on Exagen in a research note on Wednesday, July 23rd. They issued a “buy” rating and a $12.00 price objective for the company. KeyCorp raised Exagen from a “sector weight” rating to an “overweight” rating and set a $12.00 price objective for the company in a research note on Wednesday, July 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 price target on shares of Exagen in a report on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. Based on data from MarketBeat.com, Exagen presently has an average rating of “Buy” and a consensus price target of $12.00.

Exagen Price Performance

Shares of Exagen stock opened at $9.74 on Monday. The stock has a 50 day moving average of $8.70 and a 200 day moving average of $6.60. Exagen has a 12 month low of $2.38 and a 12 month high of $10.34. The firm has a market cap of $214.28 million, a PE ratio of -10.94 and a beta of 1.60. The company has a current ratio of 4.95, a quick ratio of 4.95 and a debt-to-equity ratio of 1.06.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new position in Exagen during the 1st quarter worth $25,000. Northern Trust Corp increased its holdings in Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after purchasing an additional 2,630 shares during the period. XTX Topco Ltd purchased a new position in Exagen during the 2nd quarter worth $133,000. Occudo Quantitative Strategies LP purchased a new position in Exagen during the 2nd quarter worth $138,000. Finally, Bridgeway Capital Management LLC increased its holdings in Exagen by 10.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock worth $194,000 after purchasing an additional 2,600 shares during the period. 75.25% of the stock is currently owned by hedge funds and other institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).